This is a StreetInsider.com Premium Only Page

Kalera Public (KAL) – StreetInsider.com Reports

Apr 10, 2023 04:21 PM Kalera Public (KAL) Receives Nasdaq Delisting Notice

Apr 4, 2023 09:05 AM Kalera Public (KAL) Announces Its Wholly-owned And Main Operating Subsidiary, Kalera, Inc., Files For Chapter 11 Protection To Pursue Financial And Operational Reogranization

Apr 4, 2023 08:45 AM Kalera Public (KAL) Halted, News Pending

Feb 3, 2023 11:58 AM Kalera Public (KAL) Halted on Volatility, Off Highs, Up 70%

Jan 13, 2023 11:15 AM Kalera Public (KAL) Outlines Additional Actions to Improve Profitability

Dec 23, 2022 10:55 AM Kalera Public (KAL) Shareholders Approve 1:100 Reverse Stock Split

Nov 28, 2022 09:06 AM Kalera Public (KAL) Announces Restructuring Process for German Subsidiary

Nov 7, 2022 09:37 AM Kalera Public (KAL) Reports Prelim Q3 Results

Oct 27, 2022 05:57 AM Kalera Public (KAL) Prices 68M Share Offering at $0.13/sh

Oct 18, 2022 07:36 AM Kalera Public (KAL) to Divest Seed Genetics Business and International Assets

Oct 10, 2022 06:08 AM Kalera Public (KAL) Announces 15.75M Unit Public Offering

Aug 29, 2022 07:33 AM Kalera Public (KAL) Announces Expanded Retail Distribution

Aug 22, 2022 01:04 PM Kalera AS (KAL) PT Lowered to $5 at Roth Capital

Jul 7, 2022 11:42 AM Kalera Public (KAL) Announces 2.5M Share and Warrant Placement at $4/sh

Jul 7, 2022 03:49 AM UPDATE: Roth Capital Starts Kalera AS (KAL) at Buy

Jun 28, 2022 04:15 PM Kalera Public (KAL) and Agrico Acquisition Corporation Announce Closing of Business Combination and listing on NASDAQ

Apr 11, 2008 04:15 PM Callisto (KAL) Receives Delisting Notification From AMEX; Receives 'Going Concern' From Auditor

Jun 22, 2007 04:07 PM Callisto Pharmaceuticals (KAL) Receives Non-Compliance Notification From AMEX

Jun 8, 2007 09:36 AM Callisto Pharmaceuticals (KAL) Files Suit Against Former Executive Vice President, R&D

Apr 24, 2007 08:53 AM Rodman and Renshaw Starts Callisto Pharmaceuticals (KAL) at Outperform

Feb 22, 2007 09:25 AM Callisto Pharmaceuticals (KAL) Opens L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia

Sep 26, 2006 09:33 AM Callisto Pharmaceuticals (KAL) Granted FDA Orphan Drug Designation for Company's Atiprimod

Jun 27, 2006 09:21 AM Callisto Pharmaceuticals (KAL) to Initiate Phase II Clinical Trial of Atiprimod for Advanced Carcinoid Cancer Patients

Jun 2, 2006 04:05 PM Callisto Pharmaceuticals (KAL) Reports Positive Phase I Data for Atiprimod

Jun 24, 2005 09:47 AM KAL Granted Orphan Drug Designation for Annamycin

Mar 10, 2005 08:33 AM KAL Announces $3.02 Million Private Placement